Related Experiment Video
Updated: Aug 29, 2025
Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
Published on: May 11, 2016
Cell plasticity in patients with NSCLC: The controversial origins of transformed SCLC
Xinlin Liang1, Anqi Lin2, Qiongyao Wang2
1Department of Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280 China; The First Clinical Medical School of Southern Medical University, Guangzhou, Guangdong, 510515 China.
Abstract:
In recent years, the application of targeted therapy has greatly improved the survival of NSCLC patients with known tumor mutations. However, the plasticity of tumor cells can drive them to transform into a phenotypic state that is no longer targeted by drugs. One of the mechanisms by which drug resistance occurs is the transformation from NSCLC to SCLC. This seems to occur because of the selection pressure exerted by the drugs. However, the transformation has also been observed in non-targeted patients, which challenges the origin of transformed SCLC. In the present study, the current clinical understanding of transformed SCLC is summarized along with the current understanding of its genome status and cloning history in cancer progression. This was done to explore the origins of transformed SCLC, find key molecular markers to predict the occurrence of the transformation, and permit timely adjustment of patients' treatment plans. Besides, the current clinical trials on transformed SCLC are discussed. Finally, recommendations are made on the problems that need to be solved to improve the diagnosis and treatment of patients with transformed SCLC.
Insights
Tumor cells can change from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC), leading to drug resistance. This study explores the origins and molecular markers of this transformation to improve patient treatment.
Area of Science:
- Oncology
- Cancer Biology
- Genomics
Background:
- Targeted therapy improves NSCLC survival but tumor cells can develop drug resistance.
- Phenotypic transformation, such as NSCLC to SCLC, is a key mechanism of acquired drug resistance.
- The origin of SCLC transformation, even in non-targeted patients, remains unclear.
Purpose of the Study:
- To summarize clinical understanding of SCLC transformation.
- To explore the genomic status and clonal evolution of transformed SCLC.
- To identify molecular markers for predicting transformation and guiding treatment adjustments.
Main Methods:
- Literature review of clinical understanding and genomic data.
- Analysis of cancer progression and clonal history.
- Discussion of current clinical trials for transformed SCLC.
Main Results:
- Summarizes current clinical knowledge on SCLC transformation.
- Highlights the need for understanding genomic alterations and clonal dynamics.
- Identifies gaps in predicting and managing SCLC transformation.
Conclusions:
- Understanding the origins of SCLC transformation is crucial for effective treatment.
- Key molecular markers are needed to predict and manage this phenotypic switch.
- Further research and clinical trials are essential to improve diagnosis and treatment outcomes.
More Related Videos
Related Concept Videos
01:06Induced Pluripotent Stem Cells
Somatic...
01:22iPS Cell Differentiation
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...